ClinicalTrials.gg
TerminatedNCT03722238Updated Sep 24, 2021Results posted

Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers

A Phase 3 interventional study of Ibuprofen 600 mg Immediate Release/Extended Release Caplet in Pain, sponsored by Pfizer. Terminated at 27 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-24.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Why this study was terminated
Study was terminated on 18NOV2020 after an FDA meeting where it was determined no further actual use data was needed. There were no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
2nd of 86
613 · median 100
Started
2018
with 4 others
Phase 3
22 of 86
none open now
Registered
61st of 86
by date
Lead sponsor
8 of 86
Pfizer

Among the 86 studies testing ibuprofen in Pain, this one is the 2nd largest by enrollment, is one of 5 that started in 2018, is one of 22 in phase 3, and was the 61st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

This will be an open-label, multicenter, 30-day, unsupervised AUS among targeted (at-risk) adult and adolescent consumers designed to mimic an OTC-like environment. More specifically, "at-risk" consumers, as discussed with the FDA, will comprise elderly consumers (>65 years of age), consumers with an increased risk of gastrointestinal (GI) bleeding or cardiovascular (CV) adverse events, consumers who experience severe pain, low literacy subjects, and adolescents (12-17 years of age). The total number of subjects expected to enroll into the study is approximately 820. Sites will be pharmacies in diverse geographic locations around the US. Prospective adult subjects will be recruited via general population and targeted risk condition advertising (although participants will not be informed as to specific health conditions for which they are being recruited), while adolescents will be recruited using targeted, outbound pre-recruiting telephone calls. Subjects (or the parents/guardians of prospective adolescent subjects) responding to the advertisements or recruitment calls will be initially screened by telephone, and eligibility will subsequently be verified in-person at the pharmacy site.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Male or female 18 years of age or older, has history of using oral OTC analgesics at OTC dose levels, defined as taking at least 5 doses/month on average during the past 3 months, and qualifies for inclusion in at least one risk group category, including cardiovascular, gastrointestinal bleeding, history of severe pain (≥5 episodes in last month) or >65 years of age (see Groups 1 4 in Section 3.1).

    OR Male or female 12-17 years of age and has history of using oral OTC analgesics at OTC dose levels, defined as taking at least 5 doses/month on average during the past 3 months.

  2. Evidence of a personally signed and dated document (ICD), and in the case of minor adolescent subjects (12-17 years of age or adolescent subjects residing in states where the age of majority is > than 18), an assent document, indicating that the subject and where applicable a legally acceptable representative/parent(s)/legal guardian has been informed of all pertinent aspects of the study.
  3. Willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  4. Willing (or in the case of adolescent subjects, the parent/guardian is willing) and able to purchase study medication.
  5. Agrees the product purchased is for subject's own use and not to be shared.
  6. Willing (or in the case of adolescent subjects, the parent/guardian is willing) and able to provide contact information for follow up purposes.

Exclusion criteria

Exclusion Criteria

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Subject (or parent/guardian, if applicable) cannot read, speak, and/or understand English.
  2. Trained or employed as a healthcare professional.
  3. Subject or someone else in the household is employed by a pharmaceutical company, medical practice or hospital, pharmacy, managed care or health insurance organization or a contract research organization.
  4. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or potential subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  5. Participation in other studies involving drug(s) within 6 months prior to study entry and/or during study participation.
  6. Known to ibuprofen, aspirin, or any other NSAIDs.
  7. Subjects with the following clinical conditions which place them at excessively high risk or have ≥20% 10 year risk for atherosclerotic cardiovascular disease (ASCVD), as defined by the 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk, will not be included in the study: clinically established coronary heart disease; cerebrovascular disease; peripheral artery disease; abdominal aortic aneurysm; and chronic kidney disease. Subjects who have experienced a prior non fatal cardiovascular disease event (angina, heart failure, heart disease, heart attack, stroke/) or have had heart surgery or who currently have uncontrolled high blood pressure (either by self report or by measured systolic blood pressure higher than 180 mmHg or diastolic pressure higher than 120 mmHg at the time of the enrollment interview), will also be excluded from the study.
  8. Subjects with concurrent or recent (within 30 days) use of anticoagulants, a prior history of complicated peptic ulcer, or a gastrointestinal bleeding event requiring hospitalization or blood transfusion.
  9. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product (IP) administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  10. Pregnant female subjects; breastfeeding female subjects; and male and female subjects of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for 28 days after the end of their 30-Day Use Phase or, for subjects who use the investigational product after Day 30, 28 days after the last recorded dose of investigational product.
  11. 18 years of age or older and classified as normal literacy (REALM Test score ≥61) after the normal literacy group quotas (approximately 70% of adult subjects) are full or refuses to complete the REALM Test (note there is no corresponding literacy exclusion criterion for adolescent subjects based on REALM Teen score).
  12. 18 years of age or older and classified as moderate (less frequent) oral OTC pain reliever user (\<30 doses per month on average in the preceding 3 months) after the moderate user group quotas (approximately 33% of adult subjects) are full.
  13. Not capable of swallowing a vitamin sized tablet.
  14. Refuses to participate in required assessments (such as urine pregnancy, finger stick cholesterol or blood pressure tests, or unable or unwilling to comply with electronic diary procedures).

    The following additional exclusion criteria will be applied for adolescent subjects only (12-17 years of age):

  15. Has developmental or learning disabilities that, in the judgment of the parent/guardian or the investigator, would interfere with study participation.
  16. Another adolescent child from the family is already enrolled into the study, or parent/guardian does not agree that only one adolescent child from the family or household will be enrolled into the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    Ibuprofen 600 mg Immediate Release/Extended Release Tablets

    Ibuprofen 600 mg Immediate Release/Extended Release Tablets

    Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Interventions

  • DrugIbuprofen 600 mg Immediate Release/Extended Release Caplet

    Drug page: Ibuprofen

    Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  2. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  3. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  4. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

Secondary outcomes

  1. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  2. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  3. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  4. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

    Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  5. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

    Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  6. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

    Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  7. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

    Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  8. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

    Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  9. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  10. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  11. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  12. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  13. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  14. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  15. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  16. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  17. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

    Participants did not need to necessarily use the study medication for 10 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  18. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

    Participants did not need to necessarily use the study medication for 10 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  19. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

    Participants did not need to necessarily use the study medication for 10 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  20. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

    Participants did not need to necessarily use the study medication for 10 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  21. Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

    Participants did not need to necessarily use the study medication for 7 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  22. Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

    Participants did not need to necessarily use the study medication for 7 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  23. Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

    Participants did not need to necessarily use the study medication for 7 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  24. Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

    Participants did not need to necessarily use the study medication for 7 consecutive days.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  25. Percentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day

    More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  26. Percentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day

    More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  27. Percentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day

    More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  28. Percentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day

    More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

    Time frame: From first purchase of study drug (Day 1) to Day 30

  29. Percentage of Participants in Data Analysis Set 1 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  30. Percentage of Participants in Data Analysis Set 2 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  31. Percentage of Participants in Data Analysis Set 3 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  32. Percentage of Participants in Data Analysis Set 4 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions

    Time frame: From first purchase of study drug (Day 1) to Day 30

  33. Percentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days

    Time frame: From first purchase of study drug (Day 1) to Day 30

  34. Percentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days

    Time frame: From first purchase of study drug (Day 1) to Day 30

  35. Percentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days

    Time frame: From first purchase of study drug (Day 1) to Day 30

  36. Percentage of Participants in Data Analysis Set 4 Who Used the Product on More Than 10 Consecutive Calendar Days

    Time frame: From first purchase of study drug (Day 1) to Day 30

07

Results

Posted Sep 24, 2021
Limitations and caveats
This study was terminated early due to recruitment problems and challenges. No safety concerns led to the decision to terminate.

Participant flow

Participant flow — Overall Study
MilestoneAdult Compliance-Evaluable PopulationAdolescent Users
Started6085
Safety set1985
Actual drug users1795
Completed1434
Not completed4651
Withdrew: Protocol violation10
Withdrew: Physician decision10
Withdrew: Death10
Withdrew: Lost to follow-up60
Withdrew: Partial missing data441
Withdrew: Withdrawal by subject20
Withdrew: Other40
Withdrew: Not returned to sign consent, download electronic diary application or to purchase study medication20
Withdrew: Did not meet risk classification group criteria900
Withdrew: Did not sign consent170
Withdrew: Other eligibility criteria not met pre-consent220
Withdrew: Not willing to purchase study medication1420
Withdrew: Did not qualify at re-screening and medical conditions1330

Outcome measures

PrimaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period10.6 (6.1 to 15.1)0.0 (0.0 to 0.0)
PrimaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period7.8 (3.9 to 11.8)0.0 (0.0 to 0.0)
PrimaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period7.3 (3.5 to 11.1)0.0 (0.0 to 0.0)
PrimaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period2.8 (0.4 to 5.2)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period22.9 (16.7 to 29.1)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period16.2 (10.8 to 21.6)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period14.0 (8.9 to 19.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period

Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period6.1 (2.6 to 9.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse3.4 (0.7 to 6.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse2.2 (0.1 to 4.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse2.2 (0.1 to 4.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse

Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse2.2 (0.1 to 4.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions30.7 (24.0 to 37.5)20.0 (0.0 to 55.1)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions22.3 (16.2 to 28.4)20.0 (0.0 to 55.1)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions19.0 (13.2 to 24.7)20.0 (0.0 to 55.1)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions13.4 (8.4 to 18.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions17.9 (12.3 to 23.5)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions14.5 (9.4 to 19.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions13.4 (8.4 to 18.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions7.8 (3.9 to 11.8)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

Participants did not need to necessarily use the study medication for 10 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

Participants did not need to necessarily use the study medication for 10 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

Participants did not need to necessarily use the study medication for 10 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days

Participants did not need to necessarily use the study medication for 10 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

Participants did not need to necessarily use the study medication for 7 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

Participants did not need to necessarily use the study medication for 7 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

Participants did not need to necessarily use the study medication for 7 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days1.1 (0.0 to 2.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days

Participants did not need to necessarily use the study medication for 7 consecutive days.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days0.6 (0.0 to 1.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day

More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day11.7 (7.0 to 16.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day

More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day7.8 (3.9 to 11.8)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day

More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day7.3 (3.5 to 11.1)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day

More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.

Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day2.8 (0.4 to 5.2)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Re-dosed in <12 Hours47.5 (40.2 to 54.8)0.0 (0.0 to 0.0)
Re-dosed in <10 Hours36.3 (29.3 to 43.4)0.0 (0.0 to 0.0)
Re-dosed in <8 Hours29.1 (22.4 to 35.7)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Re-dosed in <12 Hours43.0 (35.8 to 50.3)0.0 (0.0 to 0.0)
Re-dosed in <10 Hours28.5 (21.9 to 35.1)0.0 (0.0 to 0.0)
Re-dosed in <8 Hours19.6 (13.7 to 25.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Re-dosed in <12 Hours42.5 (35.2 to 49.7)0.0 (0.0 to 0.0)
Re-dosed in <10 Hours26.8 (20.3 to 33.3)0.0 (0.0 to 0.0)
Re-dosed in <8 Hours17.3 (11.8 to 22.9)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 4 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Re-dosed in <12 Hours39.7 (32.5 to 46.8)0.0 (0.0 to 0.0)
Re-dosed in <10 Hours18.4 (12.8 to 24.1)0.0 (0.0 to 0.0)
Re-dosed in <8 Hours12.3 (7.5 to 17.1)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days22.3 (16.2 to 28.4)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days22.9 (16.7 to 29.1)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame:
From first purchase of study drug (Day 1) to Day 30
Reported as:
Number · Percentage of participants
Percentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days
Percentage of participantsAdult Compliance-Evaluable PopulationAdolescent Users
Percentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days22.9 (16.7 to 29.1)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants in Data Analysis Set 4 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame:
From first purchase of study drug (Day 1) to Day 30

No measurements were reported for this outcome.

Adverse events

Collected over First purchase of study drug up to maximum of 45 days after last dose of study drug (for up to 75 days). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adult Compliance-Evaluable Population1/198 (0.5%)4/198 (2%)9/198 (4.5%)
Adolescent Users0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent serious events
Most frequent serious events
EventAdult Compliance-Evaluable PopulationAdolescent Users
Victim of crimeSocial circumstances1/1980/5
Pancreatitis acuteGastrointestinal disorders1/1980/5
DepressionPsychiatric disorders1/1980/5
HypoglycaemiaMetabolism and nutrition disorders1/1980/5
DeathGeneral disorders1/1980/5
Most frequent other events
Most frequent other events
EventAdult Compliance-Evaluable PopulationAdolescent Users
NauseaGastrointestinal disorders4/1981/5
NasopharyngitisInfections and infestations5/1980/5

Baseline characteristics

Safety set included all the participants who signed informed consent and purchased the product.

Age, Categorical
Age, Categorical(Participants)Adult Compliance-Evaluable PopulationAdolescent UsersTotal
<=18 years055
Between 18 and 65 years1500150
>=65 years48048
Sex: Female, Male
Sex: Female, Male(Participants)Adult Compliance-Evaluable PopulationAdolescent UsersTotal
Female1374141
Male61162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adult Compliance-Evaluable PopulationAdolescent UsersTotal
Hispanic or Latino10111
Not Hispanic or Latino1884192
Unknown or Not Reported000
08

Study locations

27 sites
  • Mills Pharmacy at Bluff Park
    Hoover, Alabama 35226, United States
  • Community Clinical Pharmacy
    Mesa, Arizona 85202, United States
  • ACACIA Apothecary and Wellness
    Tucson, Arizona 85704, United States
  • Coconut Grove Pharmacy
    Miami, Florida 33133, United States
  • Summerfield Pharmacy
    Riverview, Florida 33578, United States
  • Huff's Drug Store
    Ellijay, Georgia 30540, United States
  • Family Care Pharmacy
    Highland, Illinois 62249, United States
  • Rice's Pharmacy
    Beaver Dam, Kentucky 42320, United States
  • Catonsville Pharmacy
    Catonsville, Maryland 21228, United States
  • Goodrich Pharmacy
    Anoka, Minnesota 55303, United States
  • Kemper Corner Drug
    Elk River, Minnesota 55330, United States
  • Cub Pharmacy #744
    Rosemount, Minnesota 55068, United States
  • The Medicine Shoppe and Elsberry Pharmacy
    Elsberry, Missouri 63343, United States
  • Albers Medical Pharmacy
    Kansas City, Missouri 64111, United States
  • Countryside Pharmacy
    Savannah, Missouri 64485, United States
  • Texas Road Pharmacy
    Monroe, New Jersey 08831, United States
  • Dakota Pharmacy of Bismarck
    Bismarck, North Dakota 58501, United States
  • Family Prescription Center
    Bethlehem, Pennsylvania 18015, United States
  • RxXPress Health Mart Pharmacy
    Grove City, Pennsylvania 16127, United States
  • Medical Center Compounding Pharmacy & Health Center
    Cleveland, Tennessee 37311, United States
  • Buckeye Drugs
    Lebanon, Tennessee 37087, United States
  • Summerwood Pharmacy and Compounding
    Houston, Texas 77044, United States
  • The Medicine Shoppe #708
    Sherman, Texas 75092, United States
  • BrickStreet Pharmacy
    Tyler, Texas 75701, United States
  • Bountiful Drug
    Bountiful, Utah 84010, United States
  • The Medicine Center
    Salt Lake City, Utah 84121, United States
  • Montpelier Pharmacy, Inc.
    Montpelier, Virginia 23192, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Oct 2019, 10 months.

Results were first posted in Sep 2021, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2018
First posted
Oct 26, 2018
StartActual
Dec 27, 2018
Primary completionActual
Oct 28, 2019
CompletionActual
Oct 28, 2019
Results first posted
Sep 24, 2021
Last update
Sep 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03722238
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Dec 27, 2018
Primary completion
Oct 28, 2019
Completion
Oct 28, 2019
Results posted
Sep 24, 2021
Last update
Sep 24, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion